MEDISEARCHER NEWS
Italy · Medicine reimbursement · Kidney disease · 20 November 2026
In brief
- Italy’s medicines regulator, AIFA, announced on 19 November 2026 that its board had approved reimbursement for several new treatments through the Italian National Health Service (SSN).
- The decisions include Filspari (sparsentan), an oral medicine for selected adults with primary immunoglobulin A nephropathy (IgA nephropathy), a serious kidney disease.
- Filspari reimbursement is restricted to patients with persistent proteinuria of at least 1.0 g/day despite at least three months of optimised treatment with RAAS inhibitors and SGLT2 inhibitors.
- Three additional medicines received reimbursement approval for hereditary angioedema, severe inflammatory airway disease and symptoms associated with breast cancer endocrine therapy.
- AIFA also approved five indication or dosing extensions and two equivalent medicines, including a liraglutide product for type 2 diabetes.
- The decisions are national reimbursement approvals, not new European marketing authorisations. Publication of final implementing measures and practical availability arrangements remain important next steps.
Italy has approved National Health Service reimbursement for Filspari (sparsentan), a treatment for adults with primary IgA nephropathy, alongside several other medicines and expanded treatment indications.
The Italian Medicines Agency (AIFA) announced the decisions on 19 November 2026, following a meeting of its Board of Directors on 18 November.
The package includes reimbursement approval for one orphan medicine, three new active substances, five indication or dosing extensions and two equivalent medicines.
For patients, the decisions represent progress towards publicly funded access to treatments for kidney disease, hereditary angioedema, severe asthma, chronic rhinosinusitis, breast cancer treatment-related symptoms and other conditions.
However, the announcement does not establish that every medicine is immediately available through all Italian healthcare providers. The applicable reimbursement conditions, implementing measures and prescribing arrangements remain important.
In sintesi: nuove rimborsabilità dei farmaci in Italia
L’Agenzia Italiana del Farmaco (AIFA) ha annunciato il 19 novembre 2026 che il Consiglio di Amministrazione ha approvato nuove decisioni di rimborsabilità a carico del Servizio Sanitario Nazionale (SSN), comprese quelle relative a Filspari (sparsentan) per la nefropatia primaria da IgA.
La rimborsabilità di Filspari riguarda una specifica categoria di pazienti adulti con proteinuria persistente pari ad almeno 1,0 g al giorno, nonostante almeno tre mesi di trattamento ottimizzato con inibitori del sistema renina-angiotensina-aldosterone (RAAS) e inibitori SGLT2.
Le decisioni comprendono inoltre nuovi trattamenti per l’angioedema ereditario, l’asma grave e alcuni sintomi associati alla terapia endocrina del tumore al seno, oltre a estensioni di indicazione e medicinali equivalenti.
Importante: l’approvazione della rimborsabilità da parte del Consiglio di Amministrazione dell’AIFA non significa necessariamente che tutti i medicinali siano già disponibili presso ogni struttura sanitaria. Restano da verificare i provvedimenti attuativi, le date di efficacia e le condizioni di prescrizione.
Per informazioni sull’accesso al trattamento, i pazienti devono rivolgersi al proprio medico specialista o alla struttura sanitaria di riferimento.
What has AIFA approved?
According to AIFA’s official announcement, its board approved reimbursement decisions covering four medicines in the new-treatment categories, five extensions of existing treatment indications or dosing arrangements, and two equivalent medicines.
The announcement covers several different therapeutic areas rather than a single disease or medicine class.
The principal decisions are summarised below.
| Medicine | Active substance | Reimbursement decision |
|---|---|---|
| Filspari | Sparsentan | Selected adults with primary IgA nephropathy |
| Dawnzera | Donidalorsen | Prevention of recurrent hereditary angioedema attacks |
| Exdensur | Depemokimab | Severe type 2 inflammatory asthma and severe chronic rhinosinusitis with nasal polyps |
| Lynkuet | Elinzanetant | Moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy for breast cancer |
| Aspaveli | Pegcetacoplan | Expanded reimbursement for selected rare kidney diseases |
| Gazyvaro | Obinutuzumab | Active class III or IV lupus nephritis in adults, in combination with mycophenolate mofetil |
| Recarbrio | Imipenem-based antibiotic combination | Expanded reimbursement for serious resistant bacterial infections in hospitalised children, including newborns |
| Stelara | Ustekinumab | Expanded paediatric reimbursement for Crohn’s disease |
| Spinraza | Nusinersen | Approved dosing variation for spinal muscular atrophy |
| Liraglutide Dr. Reddy’s | Liraglutide | Equivalent medicine for type 2 diabetes, subject to AIFA Note 100 |
| Macitentan Medac | Macitentan | Equivalent medicine for pulmonary arterial hypertension |
The table summarises the decisions rather than reproducing every prescribing restriction. Patients and healthcare professionals should consult the final Italian reimbursement documentation for the complete eligibility criteria.
Filspari reimbursement: who qualifies in Italy?
One of the most significant decisions concerns Filspari (sparsentan), an oral treatment for primary immunoglobulin A nephropathy, also called IgA nephropathy or IgAN.
IgA nephropathy is a kidney disease in which deposits of immunoglobulin A contribute to inflammation and damage within the kidneys’ filtering structures.
Over time, some patients develop progressive loss of kidney function, potentially leading to kidney failure requiring dialysis or transplantation.
Filspari acts on two signalling pathways involved in kidney disease progression: endothelin type A receptors and angiotensin II type 1 receptors.
The medicine was already authorised in the European Union before this Italian reimbursement decision. AIFA’s announcement therefore concerns national funding and access rather than the initial approval of the medicine for use in Europe.
Specific reimbursement eligibility requirements
AIFA’s detailed decision table identifies a narrower reimbursement population than simply all adults diagnosed with IgA nephropathy.
According to the regulator, reimbursement covers adults with primary IgA nephropathy who have:
- Persistent proteinuria of at least 1.0 gram per day;
- Received optimised treatment with renin-angiotensin-aldosterone system inhibitors (RAAS inhibitors);
- Received optimised treatment with sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors); and
- Continued to have the specified level of proteinuria despite at least three months of that optimised treatment.
Proteinuria means that excess protein is present in the urine. It is an important indicator of kidney damage and a marker used when assessing the risk of disease progression.
The AIFA decision also identifies a monitoring register for Filspari, meaning treatment access and prescribing may involve specific eligibility documentation and monitoring procedures.
Patients who do not meet the defined reimbursement criteria should not assume that the medicine will automatically be funded by the Italian National Health Service.
Why is the Filspari decision important for kidney patients?
IgA nephropathy can progress at different rates. Some patients remain relatively stable for years, while others experience a gradual deterioration in kidney function despite established treatment.
Managing blood pressure, reducing proteinuria and controlling other risk factors are important parts of treatment.
Filspari offers an additional disease-specific treatment approach for eligible patients whose proteinuria remains elevated despite optimised background therapy.
Clinical studies have demonstrated reductions in proteinuria and supported the medicine’s regulatory approval for IgA nephropathy.
However, reducing proteinuria should not be confused with curing the disease. Treatment aims to slow kidney damage and reduce the risk of progression, while ongoing monitoring remains necessary.
Filspari also has important safety considerations, including potential liver injury, risks during pregnancy, low blood pressure and fluid retention. Its use requires appropriate specialist assessment and monitoring.
Patients should not stop existing kidney treatments or start Filspari without advice from their nephrologist.
Three other medicines receive reimbursement approval
Alongside Filspari, AIFA approved reimbursement for three additional active substances addressing different medical needs.
Dawnzera for hereditary angioedema
Dawnzera (donidalorsen) received reimbursement approval for routine prevention of recurrent hereditary angioedema attacks in adults and adolescents aged 12 years and older.
Hereditary angioedema is a rare inherited condition that can cause episodes of severe swelling, potentially affecting the face, limbs, abdomen or airways.
Preventive treatment aims to reduce the frequency of attacks and the burden of living with the condition.
Exdensur for severe asthma and nasal polyps
Exdensur (depemokimab) received reimbursement approval for two indications.
The first covers adults and adolescents aged 12 years and older with severe asthma characterised by type 2 inflammation and elevated eosinophils, when the disease remains inadequately controlled despite high-dose inhaled corticosteroids and another controller medicine.
The second covers adults with severe chronic rhinosinusitis with nasal polyps whose condition remains inadequately controlled despite systemic corticosteroids and/or surgery, as an additional treatment alongside intranasal corticosteroids.
These are specialist treatment indications. The decision does not mean Exdensur is appropriate for all patients with asthma, sinusitis or nasal polyps.
Lynkuet for symptoms associated with breast cancer treatment
Lynkuet (elinzanetant) received reimbursement approval for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy associated with breast cancer.
Vasomotor symptoms include hot flushes and night sweats, which can substantially affect sleep and quality of life.
The reimbursement decision is specifically linked to symptoms arising from breast cancer endocrine treatment. It should not be interpreted as unrestricted reimbursement for all menopausal symptoms.
Five existing treatment indications or dosing arrangements expanded
AIFA also approved five extensions affecting medicines already used in clinical practice.
These include:
- Aspaveli (pegcetacoplan): Reimbursement for selected adults and adolescents with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis. AIFA recognised therapeutic innovativeness for this indication.
- Gazyvaro (obinutuzumab): Reimbursement in combination with mycophenolate mofetil for adults with active class III or IV lupus nephritis.
- Recarbrio: Expanded paediatric reimbursement for serious infections caused by carbapenem-resistant Gram-negative bacteria in hospitalised patients, including newborns.
- Stelara (ustekinumab): Expanded reimbursement for paediatric patients weighing at least 40 kilograms with moderate to severe active Crohn’s disease who have not responded adequately to, or cannot tolerate, specified established treatments.
- Spinraza (nusinersen): Approval of a dosing variation for treatment of 5q spinal muscular atrophy.
These decisions affect distinct patient populations and should not be treated as blanket authorisations for all uses of the medicines.
Italy also approves reimbursement for a liraglutide equivalent
The reimbursement package includes Liraglutide Dr. Reddy’s, an equivalent medicine containing liraglutide for type 2 diabetes.
Liraglutide belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class, which is used in diabetes management and, in certain products and indications, weight management.
AIFA’s decision concerns the named liraglutide product for type 2 diabetes in adults, adolescents and children aged 10 years and older, subject to the approved treatment conditions.
The regulator lists reimbursement under AIFA Note 100.
This is not an announcement of reimbursement for liraglutide as a general weight-loss treatment. The medicine’s approved indication and applicable reimbursement restrictions remain essential.
AIFA also approved reimbursement for Macitentan Medac, an equivalent medicine used for pulmonary arterial hypertension in eligible adults and paediatric patients.
When will patients be able to receive the medicines through the Italian health service?
The AIFA announcement confirms that its Board of Directors approved the reimbursement decisions on 18 November 2026.
However, board approval and practical access are not necessarily simultaneous.
The implementation of national reimbursement decisions may depend on publication of the relevant official determinations, their effective dates, supply arrangements and prescribing or monitoring requirements.
For medicines supplied through specialist services, hospitals or regional healthcare pathways, patients may also need an assessment by an authorised clinical centre.
AIFA’s summary does not establish one common date on which all 11 medicines and decisions become operational across Italy.
Patients should therefore check with their treating specialist or relevant healthcare provider before assuming that a newly reimbursed medicine can already be prescribed and supplied under the announced conditions.
For broader context, MediSearcher’s guide to prescription costs and reimbursement across the European Union explains why medicine approval and national funding decisions are separate stages of patient access.
What does this mean for patients outside Italy?
AIFA’s decisions apply to Italy’s national reimbursement system.
They do not automatically change medicine reimbursement arrangements in Germany, France, Spain, Sweden, Poland, Ireland, Malta or other European countries.
Although medicines may have European Union marketing authorisation, national healthcare systems generally make their own decisions about pricing, reimbursement and access conditions.
For patients elsewhere in Europe, the Italian decisions may provide a useful indication of how national authorities are assessing emerging treatment options, but they do not establish eligibility for publicly funded treatment in another country.
Frequently asked questions
Has Italy approved reimbursement for Filspari?
Yes. AIFA announced on 19 November 2026 that its board had approved National Health Service reimbursement for Filspari (sparsentan) in a defined group of adults with primary IgA nephropathy.
Who qualifies for Filspari reimbursement in Italy?
AIFA’s decision covers adults with primary IgA nephropathy and persistent proteinuria of at least 1.0 g/day despite at least three months of optimised treatment with RAAS inhibitors and SGLT2 inhibitors. Additional prescribing and monitoring requirements may apply.
Is Filspari a cure for IgA nephropathy?
No. Filspari is a treatment intended to reduce disease activity and help slow kidney disease progression. It does not cure the underlying condition, and patients require ongoing medical monitoring.
Did Italy approve a new GLP-1 medicine?
AIFA approved reimbursement for Liraglutide Dr. Reddy’s, an equivalent liraglutide medicine for type 2 diabetes. The decision is subject to AIFA Note 100 and does not establish general weight-loss reimbursement.
Are the newly reimbursed medicines immediately available?
Not necessarily. AIFA’s announcement confirms board approval of reimbursement decisions, but individual implementation dates, prescribing arrangements and supply conditions must still be checked.
Does the decision apply across the European Union?
No. The reimbursement decisions apply to Italy. Other European countries maintain their own pricing, reimbursement and healthcare access arrangements.
The bottom line
Italy’s November 2026 reimbursement decisions represent an important development for patients who need access to specialist medicines, particularly those living with rare kidney disease and other conditions requiring targeted treatment.
Filspari is a notable addition because AIFA has defined a reimbursement pathway for selected adults with IgA nephropathy whose proteinuria remains elevated despite optimised established treatment.
The wider package also expands publicly funded treatment options across rare diseases, severe inflammatory conditions, oncology-related symptoms, paediatric care and diabetes.
The key distinction is that AIFA has approved reimbursement decisions, but individual eligibility, implementation dates and practical medicine availability still need to be established through the relevant national arrangements.
Reviewed by: Dr Mattias Hagman, PhD
Editorial review: MediSearcher reviewed AIFA’s 19 November 2026 announcement and its detailed reimbursement decision table from the 18 November board meeting, alongside European Medicines Agency information on Filspari. Particular attention was given to the eligibility restrictions for IgA nephropathy, the distinction between new medicines and indication extensions, the scope of the liraglutide reimbursement decision, and the difference between board approval and practical patient availability.
Last reviewed: 20 November 2026
Sources and verification
MediSearcher consulted the following primary regulatory sources:
- Italian Medicines Agency (AIFA): Board approves reimbursement for an orphan kidney medicine, three new active substances, five extensions and two equivalent medicines, 19 November 2026 — primary announcement identifying the medicines and national reimbursement decisions.
- Italian Medicines Agency (AIFA): Summary table of new medicines and indication extensions, Board meeting of 18 November 2026 — detailed reimbursement indications, eligibility restrictions, supply classifications and monitoring requirements.
- European Medicines Agency: Filspari (sparsentan) European Public Assessment Report — EU marketing authorisation, therapeutic indication and regulatory product information.
This article provides general health and regulatory information and does not replace individual medical advice. Reimbursement approval does not guarantee immediate medicine availability or eligibility for every patient. Treatment decisions, prescribing restrictions and access arrangements should be discussed with an appropriately qualified healthcare professional. National reimbursement rules and medicine availability may change after publication.